Posts

Signaling Through the Type 2 Cannabinoid Receptor Regulates the Severity of Acute and Chronic Graft versus Host Disease

Authors: Cheng Yin Yuan, Vivian Zhou, Garrett Sauber, Todd M Stollenwerk, Richard Komorowski, Alicia López, Rosa Maria Tolon, Julian Romero, Cecilia J Hillard, William R Drobyski Published in Blood  October 2020 Abstract Graft versus host disease (GVHD) pathophysiology is a complex interplay between cells that comprise the adaptive and innate arms of the immune system….

Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol.

Authors: Patrycja Bielawie, Ewa Harasim-Symbor, Adrian Chabowski
Frontiers in Endocrinology, 4 March 2020

Currently, an increasing number of diseases related to insulin resistance and obesity is an alarming problem worldwide. It is well-known that the above states can lead to the development of type 2 diabetes, hypertension, and cardiovascular diseases. An excessive amount of tria…

The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases.

Authors: Maura Argenziano, Chiara Tortora, Giulia Bellini, Alessandra Di Paola, Francesca Punzo, et al
International Journal of Molecular Sciences, 23 November 2019

Endocannabinoid system consists of cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors, their endogenous ligands, and the enzymes responsible for their synthesis and degradation. CB2, to a great extent, and CB1, to a lesser extent, are involved in regulating the im…

Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications.

Authors: Vivek S. Kumawat, Ginpreet Kaur
European Journal of Pharmacology, 5 November 2019

The biological effects of endocannabinoid system are mediated by two types of receptors, cannabinoid 1 (CB1) and cannabinoid 2 receptor (CB2). They play a pivotal role in the management of pain, inflammation, cancer, obesity and diabetes mellitus. CB2 receptor activity downreg…